Novartis Targets Large Scale UK Roll Out of Cholesterol Drug
January 13 2020 - 01:40PM
Dow Jones News
By Carlo Martuscelli
Novartis AG (NOVN.EB) said Monday that it is aiming to ensure
widespread access in the U.K. to its investigational cholesterol
medicine Inclisiran as soon as it secures regulatory approval.
The Swiss drug maker said it wants to collaborate with the
British government to ensure the supply and administration of the
cholesterol-reducing drug to all eligible patients in the country's
National Health Service.
Inclisiran is currently in Phase 3 clinical study. The
pharmaceutical company said it expects to file for marketing
approval in the first quarter of this year. The first indication
that is being sought is to provide the cholesterol-lowering drug to
at-risk patients with atherosclerotic cardiovascular disease
Novartis gained the asset when it bought Medicines Co. in a $9.7
billion deal in November. The current roll-out plans are based on a
memorandum of understanding that the acquired company signed with
the U.K. government.
A company spokesperson said that the Swiss drug maker is engaged
in talks to finalize the more detailed aspects of the agreement
with British authorities.
Plans also include a new clinical trial for patients that are at
a high-risk of having their first cardiac event.
Write to at carlo.martuscelli@wsj.com; @carlomartu
(END) Dow Jones Newswires
January 13, 2020 13:25 ET (18:25 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
Novartis (NYSE:NVS)
Historical Stock Chart
From Feb 2024 to Mar 2024
Novartis (NYSE:NVS)
Historical Stock Chart
From Mar 2023 to Mar 2024